Description: This article reviews the topics discussed at the December 2004 meeting of the Life and Health Actuarial task force. The covered topics include Actuarial Guideline 38 and Reserves for Variable Annuities C-3 Phase 2 reserves.

Description: Discusses Product Development Section activities at the upcoming SOA Annual Meeting in the fall.

Description: This article discusses a recently completed RGA in-depth study that looked at assumptions and experience for lapses and mortality at the end of the level premium period for level term business.

Description: This article provides a summary of the results from a recent Milliman survey. Survey results provide UL/IUL carriers with a benchmark to evaluate their practices relative to those prevalent in the industry.

Description: Defines Accelerated Underwriting programs as a transformational trend, and outlines a process for evaluating mortality implications of such programs.

Description: Hear from the chairperson on themes in the June 2017 issue of Product Matters published by the Product Development Section.

Description: This article describes how actuaries can get involved in section research including participation on a Project Oversight Group (POG).

Description: How do you develop an accelerated underwriting program? The Accelerated Underwriting Program Development Seminar held in Tampa, Florida on May 22, 2019 answers this question through a series of sessions across various disciplines, including underwriting, actuarial, project management, marketing and data science. This article outlines the key takeaways from each of the industry experts.

Description: Oliver Wyman surveyed the life insurance industry in 2Q 2018 on emerging life PBR practices. Key takeaways and a deeper dive on select practices are provided.

Description: In this article we provide a market overview of these three living benefit riders, discuss key product development and pricing considerations, explore the advantages of offering many living benefit riders on a single life insurance policy, and review considerations when filing these products for review and approval for entering the market.